GLP-1 and liraglutide reduced atrial fibrillation and prevented atrial remodeling in type 2 diabetic db/db mice.
Does GLP-1 or liraglutide reduce atrial fibrillation and prevent atrial remodeling in type 2 diabetic db/db mice?
GLP-1 and liraglutide reduce atrial fibrillation susceptibility and prevent atrial remodeling in a mouse model of type 2 diabetes, suggesting a potential protective effect in humans.
Absolute Event Rate: 0% vs 0%
Atrial fibrillation (AF) is highly prevalent in type 2 diabetes where it increases morbidity and mortality. Glucagon-like peptide (GLP)-1 receptor agonists are used in the treatment of type 2 diabetes (T2DM), but their effects on AF in T2DM are poorly understood. The present study demonstrates type 2 diabetic db/db mice are highly susceptible to AF in association with atrial electrical and structural remodeling. GLP-1, as well as the long-acting GLP-1 analogue liraglutide, reduced AF and prevented atrial remodeling in db/db mice. These data suggest that GLP-1 and related analogues could protect against AF in patients with T2DM.
Bohne et al. (Wed,) reported a other. GLP-1 and liraglutide reduced atrial fibrillation and prevented atrial remodeling in type 2 diabetic db/db mice.